

Patent application enters PCT phase, SpectraCure ensures development and work

SpectraCure's work and development proceeds with several parallel projects. A patent application which covers a new technology that improves upon the Company's IDOSE technology is now progressing to the so-called PCT phase, which is a way of coordinating patent applications in all the countries of the world. This is a result of the positive outcome of the European Patent Office's review.

The patent application covers a new technology which increases the accuracy of the Company's IDOSE technology further. The technology entails that IDOSE is able to detect and compensate for small haemorrhages that occur in tissue in conjunction with the treatment more clearly than before, by way of measurements and software. The IDOSE technology is at the heart of SpectraCure's method for treatment of prostate cancer with photodynamic therapy (PDT). The technology involves monitoring of the prostate tissue throughout the treatment; a series of measurements are conducted to ensure the administration of the proper dose required to eliminate the tumor without causing harm to surrounding tissue.

The things under our control are in order

In connection with the coronavirus outbreak, measures have been taken to protect the staff of the Company, to take our social responsibility and to reduce any negative impact of the outbreak on the Company's operations.

- The things under our control are in order, such as the development of our software and hardware, and work is proceeding according to plan. We are supporting the study coordinators and we are trying to facilitate their work with the clinical trial. Our close contact and good cooperation will hopefully result in an accelerated patient recruitment when the outbreak eventually fades. Patients in active follow-up remain in the study. To ensure patient safety, the follow-up of patients is conducted over the phone, and blood samples of patients are taken by their general practitioners to the extent that it is possible to do so, says Masoud Khayyami, CEO of SpectraCure.

SpectraCure continues to monitor the corona situation very closely.

For additional information about the patent application, see <https://spectracure.r/spectracure-files-for-a-new-patent>

This information is information that SpectraCure AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on 7 April 2020.

For further information, please contact:

SpectraCure AB publ, CEO, Masoud Khayyami, phone: +46 (0) 70 815 21 90

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46(0) 8 503 000 50

This information is information that SpectraCure AB is required to disclose under the EU Market Abuse Regulation. The information was provided, through the contact of the above contact person, for publication on April 7, 2020.

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as "Interstitial Photodynamic Therapy", PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region. www.spectracure.com